Nanobiotix S.A. (NANO.PA)
EUR 3.48
(1.93%)
EUR 3.48
(1.93%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 93.89 Million EUR | 57.1% |
| 2022 | 59.76 Million EUR | -41.21% |
| 2021 | 101.67 Million EUR | -24.08% |
| 2020 | 133.92 Million EUR | 138.84% |
| 2019 | 56.07 Million EUR | 21.39% |
| 2018 | 46.19 Million EUR | -19.61% |
| 2017 | 57.46 Million EUR | 89.02% |
| 2016 | 30.4 Million EUR | 15.08% |
| 2015 | 26.41 Million EUR | -28.7% |
| 2014 | 37.05 Million EUR | 398.12% |
| 2013 | 7.43 Million EUR | -46.96% |
| 2012 | 14.02 Million EUR | 381.38% |
| 2011 | 2.91 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 86.68 Million EUR | 0.0% |
| 2023 FY | 93.89 Million EUR | 57.1% |
| 2023 Q4 | 93.89 Million EUR | 0.0% |
| 2023 Q2 | 40.4 Million EUR | 0.0% |
| 2022 Q2 | 80.56 Million EUR | 0.0% |
| 2022 FY | 59.76 Million EUR | -41.21% |
| 2022 Q4 | 59.76 Million EUR | 0.0% |
| 2021 Q2 | 123.82 Million EUR | 0.0% |
| 2021 FY | 101.67 Million EUR | -24.08% |
| 2021 Q4 | 101.67 Million EUR | 0.0% |
| 2020 Q2 | 44.7 Million EUR | 0.0% |
| 2020 FY | 133.92 Million EUR | 138.84% |
| 2020 Q4 | 133.92 Million EUR | 0.0% |
| 2019 Q2 | 75.12 Million EUR | 0.0% |
| 2019 FY | 56.07 Million EUR | 21.39% |
| 2019 Q4 | 56.07 Million EUR | 0.0% |
| 2018 FY | 46.19 Million EUR | -19.61% |
| 2018 Q2 | 43.87 Million EUR | 0.0% |
| 2018 Q4 | 46.19 Million EUR | 0.0% |
| 2017 FY | 57.46 Million EUR | 89.02% |
| 2017 Q4 | 57.46 Million EUR | 0.0% |
| 2017 Q2 | 42.38 Million EUR | 0.0% |
| 2016 Q2 | 37.04 Million EUR | 0.0% |
| 2016 FY | 30.4 Million EUR | 15.08% |
| 2016 Q4 | 30.4 Million EUR | 0.0% |
| 2015 FY | 26.41 Million EUR | -28.7% |
| 2015 Q4 | 26.41 Million EUR | 0.0% |
| 2015 Q2 | 32.71 Million EUR | 0.0% |
| 2014 Q4 | 37.05 Million EUR | 0.0% |
| 2014 Q2 | 30.26 Million EUR | 0.0% |
| 2014 FY | 37.05 Million EUR | 398.12% |
| 2013 Q4 | 7.43 Million EUR | 0.0% |
| 2013 Q2 | 10.23 Million EUR | 0.0% |
| 2013 FY | 7.43 Million EUR | -46.96% |
| 2012 FY | 14.02 Million EUR | 381.38% |
| 2012 Q4 | 14.02 Million EUR | 0.0% |
| 2011 FY | 2.91 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -538.321% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 71.291% |
| Adocia SA | 24.95 Million EUR | -276.25% |
| Aelis Farma SA | 26.28 Million EUR | -257.281% |
| Biophytis S.A. | 11.93 Million EUR | -686.671% |
| Advicenne S.A. | 12.4 Million EUR | -656.807% |
| genOway Société anonyme | 31.84 Million EUR | -194.881% |
| IntegraGen SA | 8 Million EUR | -1073.661% |
| Medesis Pharma S.A. | 1.92 Million EUR | -4774.386% |
| Neovacs S.A. | 47.53 Million EUR | -97.538% |
| NFL Biosciences SA | 3.97 Million EUR | -2264.79% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -529.635% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -2406.078% |
| Sensorion SA | 46.49 Million EUR | -101.955% |
| Theranexus Société Anonyme | 7.23 Million EUR | -1197.325% |
| TME Pharma N.V. | 2.49 Million EUR | -3669.45% |
| Valbiotis SA | 33.24 Million EUR | -182.414% |
| TheraVet SA | 7.53 Million EUR | -1146.279% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -166.193% |
| argenx SE | 4.11 Billion EUR | 97.717% |
| BioSenic S.A. | 9.55 Million EUR | -882.289% |
| Celyad Oncology SA | 16.28 Million EUR | -476.692% |
| DBV Technologies S.A. | 165.65 Million USD | 43.316% |
| Galapagos NV | 4.35 Billion EUR | 97.845% |
| Genfit S.A. | 173.87 Million EUR | 45.996% |
| GeNeuro SA | 6.31 Million EUR | -1387.383% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -96.927% |
| Innate Pharma S.A. | 184.19 Million EUR | 49.022% |
| Inventiva S.A. | 69.13 Million EUR | -35.809% |
| MaaT Pharma SA | 42.93 Million EUR | -118.716% |
| MedinCell S.A. | 36.94 Million EUR | -154.133% |
| Onward Medical N.V. | 43.62 Million EUR | -115.217% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 12.164% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -14.648% |
| Oxurion NV | 6.55 Million EUR | -1333.542% |
| Pharming Group N.V. | 426.33 Million EUR | 77.976% |
| Poxel S.A. | 4.82 Million EUR | -1846.859% |
| GenSight Biologics S.A. | 9.08 Million EUR | -933.311% |
| Transgene SA | 45.21 Million EUR | -107.659% |
| Financière de Tubize SA | 1.92 Billion EUR | 95.11% |
| UCB SA | 15.53 Billion EUR | 99.396% |
| Valneva SE | 469.39 Million EUR | 79.996% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -204.574% |